Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials
Authors:
Z. Adam 1; V. Ščudla 2; M. Krejčí 1; Z. Čermáková 3; L. Pour 1; Z. Král 1
Authors place of work:
Interní hematologická a onkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Mayer, CSc.
1; III. interní klinika - nefrologie, revmatologie a endokrinologie Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Josef Zadražil, CSc.
2; Oddělení klinické biochemie FN Brno, pracoviště Bohunice, přednosta doc. MUDr. Milan Dastych, CSc., MBA
3
Published in the journal:
Vnitř Lék 2013; 59(1): 37-58
Category:
Review
Summary
Until 2011, the gold standard of treatment for patients with AL amyloidosis was the combination of alkylating cytostatics (melphalan or cyclophosphamide) and dexamethasone. For a selected group of patients under 65 years of age with only moderate damage to their body caused by amyloid and with good cardiac function (EF> 40%), high-dose chemotherapy with autologous hematopoietic cell transplantation seems to be optimal. Patients with AL amyloidosis and low bone marrow plasma cell count generally undergo the harvest of hematopoietic cells from peripheral blood, followed by high-dose chemotherapy immediately after they are diagnosed. In contrast to multiple myeloma, high-dose chemotherapy is not preceded by several months of conventional treatment. The year 2012 witnessed a release of reports about extensive experience with new drugs that were used in Phase I and Phase II clinical trials, and in isolated cases also in Phase III, for the treatment of patients with AL amyloidosis. Based on these studies it can be concluded that among the new available drugs (bortezomib, thalidomide and lenalidomide) bortezomib is the drug with the greatest curative effect in patients with AL amyloidosis; it achieved 24–37% of complete remissions in monotherapy. The greatest number of treatment responses was reported during the treatment that combined bortezomib, alkylating cytostatics and dexamethasone. This treatment showed significantly more treatment responses during the first-line drug therapy than during therapies that followed. Clinical trials with lenalidomide combined with other drugs saw a lower number of treatment responses than the number described in treatment with bortezomib combined with other drugs. That is the reason why lenalidomide combinations are not considered the optimal first-line therapy, with the exception of AL amyloidosis with bortezomib contraindication (severe neuropathy caused by AL amyloidosis). It was confirmed that lenalidomide combined with other drugs could cause remission in patients whose disease was resistant to the initial bortezomib therapy. Lenalidomide (or alternatively also thalidomide) can therefore be used as second-line therapy if bortezomib therapy proves unsuccessful, with the possibility of achieving a complete remission. The increase in the number of complete remissions brought about by bortezomib therapies in patients with AL amyloidosis poses a question about which treatment should be used for younger patients with only moderate damage to their body, i.e. high-dose chemotherapy with autologous hematopoietic cell transplantation or combined treatment with bortezomib. Additional comparative studies are required to be able to answer that question and determine which of the aforesaid therapy modalities is optimal. A question still remains whether the increase in the number of complete remissions due to bortezomib will also bring about longer survival comparable to the results of high-dose chemotherapy treatment with autologous hematopoietic cell transplantation.
Key words:
AL amyloidosis – bortezomib – lenalidomide – thalidomide – high-dose chemotherapy with autologous transplantation
Zdroje
1. Ščudla V, Pika. T Současné možnosti léčby systémové AL amyloidózy. Vnitř Lék 2009; 55: (Suppl. 1): 77–87.
2. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583–596.
3. Abraham RS, Geyer SM, Price-Troska L et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome of light chain-associated amyloidosis. Blood 2003; 101: 3801–3808.
4. 1Comenzo RL, Zhang Y, Martinez C et al. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line use and clonal plasma cell burden. Blood 2001; 98: 714–720.
5. Bellotti V, Chiti F. Amyloidogenesis in its biological environment: challenging a fundamental issue in protein mis-folding diseases. Curr Opin Struct Biol 2008; 18: 771–779.
6. Adam Z, Ščudla V. Klinické projevy a diagnostika AL-amyloidózy a některých dalších typů amyloidóz. Vnitř Lék 2001; 47: 36–45.
7. Tichý M. Primární amyloidóza. Lék Zpr UK Hradec Králové 1999; 44: 99–107.
8. Kroupa R, Dastych M, Šenkyřík M et al. Systémové amyloidóza s dominující klinickou manifestací v trávicím traktu. Vnitř Lék 2005; 51: 588–592.
9. Ryšavá R Amyloidóza ledvin. Postgrad Med 2006; 8: 207–212.
10. Ryšavá R. Léčba paraproteinemické nefropatie a primární amyloidózy ledvin. Aktual v Nefrol 2005; 11: 62–65.
11. Linhartová K, Daum O. Srdeční amyloidóza. Cor et Vasa 2005; 47: 328.
12. Sideras K, Gertz MA. Amyloidosis. Adv Clin Chem 2009; 47: 1–44.
13. Lavatelli F, Perlman DH, Spencer B. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 2008; 7: 1570–1583.
14. Anesi E, Palladini G, Perfetti V et al. Therapeutic advances demand accurate typing of amyloid deposits. Am J Med 2001; 111: 243–244.
15. Lachman HJ, Booth DR, Booth SE et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346; 23: 1786–1791.
16. Vrana JA, Zeldenrust SR, Theis JD et al. Diagnosis and classification of amyloidosis in abdominal subcutaneous fat specimens using mass spectrometry based proteomics. Blood 2008; 112: 937, abstr. 2710.
17. Linke RP. On typing amyloidosis using immunohistochemistry. Detailled illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem 2012; 47: 61–132.
18. Sethi S, Vrana JA, Theis JD et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 2012; 82: 226–234.
19. Ribeiro-Silva C, Gilberto S, Gomes RA et al. The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry. Amyloid 2011; 18: 191–199.
20. Lavatelli F, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid 2011; 18: 177–782.
21. Westermark P. Amyloid diagnosis, subcutaneous adipose tissue, immunohistochemistry and mass spectrometry. Amyloid 2011; 18: 175–176.
22. Brambilla F, Lavatelli F, Di Silvestre D et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012; 119: 1844–1847.
23. Lavatelli F, Valentini V, Palladini G et al. Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid 2011; 18: (Suppl. 1): 59–61.
24. Klein CJ, Vrana JA, Theis JD et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol 2011; 68: 195–199.
25. Sethi S, Theis JD, Leung N et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5: 2180–2187.
26. Vrana JA, Gamez JD, Madden BJ et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 4957–4959.
27. Kyle RA, Linos A, Beard CM et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County Minnesota. Blood 1992; 78: 1817–1822.
28. Magy-Bertrand N, Dupond JL, Mauny F et al. Incidence of amyloidosis over 3 years. The Amypro study. Clin Experiment Rheumatology 2008; 26: 139–142.
29. Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol 2008; 19: (Suppl. 4): 63–66.
30. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520–2530.
31. Van Gameren I, van Rijswijk MH, Bijzet J et al. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009; 94: 1094–1100.
32. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myelom and releated disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003; 121: 749–457.
33. Kyle RA. Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3–9.
34. Gertz MA, Comenzo R, Falk RH. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis. A consensus opinion from the 10th international symposium on amyloid and amyloidosis. Amer J Hematol 2005; 79: 319–328.
35. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010; 17: (Suppl. 1): 48–49.
36. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202–1207.
37. Gertz MA, Kyla RA, Greip PP. Response rates, and survival in primary systemic amyloidosis. Blood 1991; 77: 257–262.
38. Gertz MA, Lacy MQ, Lust JA et al. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melpahalan, cylophosphamide and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 1999; 17: 262–267.
39. Dhodapkar MV, Hussein MA, Rasmussen E et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520–3526.
40. Palladini G, Perfetti V, Obici L et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938.
41. Goodman H, Lachmann H, Bradsell AR et al. Intermediate dose melpahalan and dexamethasone treatment in 144 patients with systemic AL-amyloidosis. Blood 2004; 104: 755–759.
42. Goodman H, Wechalekar A, Lachmann H et al. Clonal disease response and clinical outcome in 229 patients with AL-amyloidosis treated with VAD-like chemotherapy Hematologica 2008; 90: 201–203.
43. Palladini G, Anesi E, Perfetti V et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001; 113: 1044–1046.
44. Palladini G, Russo P, Nuvolone M et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110: 787–788.
45. Palladini G, Russo P, Foli A et al. Treatment with oral melphalan and dexamethasone in an extended population with AL amyloidosis. Blood 2009; 114: (Suppl. N 22): 1496, abstr. 3889.
46. Sanchowarala V, Seldin DC, Sloan JM et al. Oral cyclic melphalan and dexametasone treatment in the treatment of patients with high dose amyloidosis, ineligible for high dose melphalan and stem cell transplantation. Blood 2009; 114: (Suppl. N 22): 748, abstr. 1883.
47. Sanchorawala V, Sedlin CD, Berk JL et al. Oral cyclic melphalan and dexametasone for pacient with AL amyloidosis. Clin Lymphoma Myeloma Leukemia 2010; 10: 469–472.
48. Sitia R, Braakman I. Duality control in the endoplasmatic reticulum protein factory. Nature 2003; 426: 891–894.
49. Breckenridge DG, Germain M, Mathai JP et al. Regulation of apoptosis by endoplasmatic reticulum pathway Oncogene 2003; 22: 8608–8618.
50. Teixeira PR, Cerca F, Santos SD et al. Endoplasmatic reticulum stress associated with extracelullar aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem 2006; 281: 21998–22003.
51. Huang CJ, Haataje L, Gurlo T et al. Induction of endoplasmatic reticulum stress-induced beta-cell apoptosis and accumulation of polyubiquitinated protein by human islet amyloid polypeptide. Am J Physiol Endocrinol Metab 2007; 293: E1656–E1662.
52. Keller JN, Hanni KB Markesbery WR. Impaired proteasome function in Alzheimer´s disease. J Neurochem 2000; 75: 436–439.
53. Casas S, Gomis R, Gribble FM et al. Impairment of the ubiquitin-proteasome pathway is a dowstream endoplasmatic reticulum stress response induced by extracellular human islet amyloid polypeptide and contributes to pancreatic beta-cell apoptosis. Diabetes 2007; 56: 2284–2294.
54. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 2007; 92: 1302–1307.
55. Bianchi G, Oliva L, Casctio P et al. The proteasome load versus capaticy balance determinates apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009; 113: 3040–3049.
56. Reece D, Hegenbart U, Merlini G et al. Weekly and twice-weekly bortezomib in patients with systemic AL-amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489–1497.
57. Reece DE, Hegenbart U, Sanchorawala V et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865–873.
58. Kastritis E, Anagnostopoulos A, Rousnou M et al. Treatment of ligh chain deposition disease with the combination of bortezomibe and dexamethasone. Blood 2007; 110: (N.11 Suppl.): abstr. 64.
59. Kastritis E, Anagnostopoulos A, Roussou M et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351–1358.
60. Wechalekar AD, Lachmann HJ, Offer M et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295–298.
61. Kastritis E, Wechalekar AD, Dimopoulos MA et al. Significant activity of bortezomib--based therapy in patients with primary systemic AL-amyloidosis. Blood 2008; 112: 321, abstr. 869.
62. Zonder JA, Sanchorawala, V, Snyder RM et al. Melphalan, dexamethosone plus bortezomib induces hematologic and organ response in AL-amylolidosis with tolerable neurotoxicity. Blood 2009; 114: (Suppl. N 22): 310, abstr. 746.
63. Singh V, Saad A, Palmer J et al. Response to bortezomib based induction therapy in newly diagnosed light chain (AL) amyloidosis. Blood 2009; 114: (Suppl. N 22): 740, abstr. 1867.
64. Kastritis E, Wechalekar AD, Dimopoulos MA et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 1031–1037.
65. Lamm W, Willenbacher W, Zojer N et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Blood 2009; 114: (Suppl. N 22): 1121, abstr. 2871.
66. Palladini G, Foli A, Russo P et al. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. Clin Lymphoma Myeloma Leuk 2011; 11: 3–5.
67. Moscetti A, Saltarelli F, Bianchi MP et al. Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse. Amyloid 2011; 18: (Suppl 1): 147–149.
68. Abonour R, Kramer G, Suvannasankha A et al. Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience. Amyloid 2011; 18: (Suppl. 1): 146.
69. Coriu D, Badelita S, Talmaci R et al. Bortezomib in systemic AL amyloidosis: a single center experience. Amyloid 2011; 18: (Suppl. 1): 143–145.
70. Dubrey SW, Reece DE, Sanchorawala V et al. Velcade Can 2007 Study Group. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM 2011; 104: 957–970.
71. Maramattom LV. Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL). Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 1880.
72. Palladini G. Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients. Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 3977.
73. Re A. Bortezomib-Containing Regimens in the Treatment of AL Amyloidosis: A Single Center Experience. Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 4614.
74. Cossor FI. Weekly Combination Chemotherapy with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for Newly Diagnosed Patients with Advanced Cardiac Disease Due to Systemic ALAmyloidosis. Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 5139.
75. Jaccard A. Efficacy of Bortezomib/Cyclophosphamide/Dexamethasone (VCD) Chemotherapy in Naive Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III). Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 5126.
76. Mikhael JR, Schuster SR, Jimenez-Zepeda VH et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391–4394.
77. Venner CP, Lane T, Foard D et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387–4390.
78. Dimopoulos MA, Kastritis E. Bortezomib for AL amyloidosis: moving forward. Blood 2011; 118: 827–828.
79. Lamm W, Willenbacher W, Lang A et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011; 90: 201–206.
80. Jimenez-Zepeda VH, Reeder CB, Mikhael JR et al. Cyclophophamide, bortezomib and dexamethasone induces rapid and complete response in patients with amyloidosis non eligible for peripheral stem cell transplant. Blood 2009; 114: (Suppl. N 22): 737, abstr. 1857.
81. Venner ChP, Lane T, Foard D et al. A matchen comparison of cyclophosphamide, bortzomib and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in the treatment of Mayo cardiac stage II patients with AL-amyloidosis. Blood 2012; Suppl. Abstracts from the 54th ASH annual meeting December 8–11, Atlanta 2012, Abstr. N 2966.
82. Landau H, Hassoun H, Bello C et al. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid 2011; 18 (Suppl. 1): 1300–1301.
83. Ghose A, Tariq Z, Taj A et al. Acute dyspnea from treatment of AL amyloidisis with bortezomib. Am J Ther 2011; 18: e123–e125.
84. Dispenzieri A, Lacy MQ, Rajkumar SV et al. Poor tolerance to high dose thalidomide in patients with light chain associated (AL) amyloidosis. Amyloid 2003; 10: 257–261.
85. Dispenziery A, Lacy MQ, Zeyer SM et al. Low dose single agent thalidomid is tolerated in patients with primary amyloidosis, but responses are limited. Blood 2004; 104: 4920–4922.
86. Seldin DC, Choufani EB, Dember LM et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003; 3: 241–246.
87. Palladinin G, Perfetti V, Perlini S et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis Blood 2005; 105: 2949–2951.
88. Wechalekar AD, Goodman HJ, Lachmann HJ et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457–464.
89. Palladini G, Russo P, Lavatelli F et al. Treatment of patients with cardiac AL-amyloidosis with oral melphalan, dexamethasone and thalidomide. Ann Hematol 2009; 88: 347–350.
90. Gibbs SDJ, Sattianayagam PT, Lachmann H et al. Risk adapted cyclophosphamide, thalidomide and dexamethasone (CTD) for treatment of systemic AL-amyloidosis: long term outcome of 202 Patients. Blood 2008; 112: 611, abstr. 1733.
91. Gibbs SDJ, Gillmore J, Satttianayagam PT et al. in AL-amyloidosis both oral melphalan and dexametzasone and risk adapted cyclophosphamide, thalidomide, and dexamethasone (CTD) have similar efficacy as upfront treatment Blood 2009; 114: (Suppl. N 22): 310, abstr. 745.
92. Gibbs SDJ, Gillmore JD, Sattianayagam PT et al. CTD versus Mel-Dex as upfront treatment in AL-amyloidosis.: a matched case-control study. Amyloid 2010; 17: 4922–4924.
93. Gillmore J, Cocks K, Gibbs DJB et al. Cyclophosphamide, thalidomide and dexamethasone (CTD) versus melphalan and dexamethasone (MD) for newly diagnosed systemic AL amyloidosis. Result from the UK amyloidosis treatment trial. Blood 2009; 114: (Suppl. N 22): 1120, abstr. 2869.
94. Cohen AD, Zhou P, Chou J et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone ± thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 2007; 139: 224–233.
95. Dispenzieri A, Lacy MQ, Zeldenrust S et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465–470.
96. Sanchorawala V, Wright DG, Rosenzweig M et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492–496.
97. Dispenzieri L, Lacy M, Zeldenrust SR et al. Long term follow up of patients with immunoglobulin light chain amyloidosis treated with lenalidomide and dexamethasone. Blood 2008; 112: 612, abstr. 1737.
98. Kastritis E, Zahoura F, Rousnou M et al. Phase I/II study of lenalidomid, intermediate dose of dexamethasone and low dose cyclophosphamide for the treatment of AL-amyloidosis. Blood 2008; 112: 611, abstr. 1734.
99. Schoenland SO, Bochler T, Ditrich S et al. Single center experience of lenalidomide/dexametazone treatment in 40 patients with light chain amyloidosis. High toxicity in patients with impaired renal and cardiac function. Blood 2008; 112: 612, abstr. 1736.
100. Moreau P, Jaccard A, Benboubker L et at. Lenalidomide with melphalan and dexamethasone in patients with newly diagnosed light chain amyloidosis. A multicenter phase I/II dose escalation study. Blood 2009; 114: (Suppl. N 22): 177, abstr. 427.
101. Kastritis E, Roussou M, Migkou M et al. A phase I/II study of lenalidomide with low dose dexamethasone and cyclophosphamide for patients with primary systemic light chain amyloidosis. Blood 2009; 114: (Suppl. N 22): 177, abstr. 428.
102. Sloan JM, Sanchowarala V, Girnius S et al. Melphalan, lenalidomide and dexamethasone combination therapy in patients with AL amyloidosis. Blood 2009; 114: (Suppl. N 22): 737, abstr. 1859.
103. Palladini G, Russo P, Bragotti LZ et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL-amyloidosis. Blood 2009; 114: (Suppl. N 22): 1117, abstr. 2863.
104. Kumar S, Hayman SR, Buaudi F et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone in patients with light chain amyloidosis. Blood 2009; 114: (Suppl N 22): 1482, abstr. 3853.
105. Sanchorawala V, Finn KT, Fennessey S et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 2010; 116: 1990–1991.
106. Palladini G, Russo P, Foli A et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 2012; 91: 89–92.
107. Kastritis E, Terpos E, Roussou M et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012; 119: 5384–5390.
108. Kumar SK, Hayman SR, Buadi FK et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long--term results from a phase 2 trial. Blood 2012; 119: 4860–4867.
109. Moreau P, Jaccard A, Benboubker L et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010; 116: 4777–4782.
110. Specter R, Sanchorawala V, Seldin DC et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2011; 26: 881–886.
111. Batts ED, Sanchorawala V, Hegerfeldt Y et al. Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 2008; 49: 1108–1115.
112. Tapan U, Seldin DC, Finn KT et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood 2010; 116: 5071–5072.
113. Finsterer J, Höftberger R, Stöllberger C et al. Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease. J Oncol Pharm Pract 2012; Apr 13, 112–115. [Epub ahead of print].
114. Sanchorawala V, Skinner M, Quillen K et al. Long-term outcome of patients with AL amyloidosis treated with melphalan and stem cell transpalntation. Blood 2007; 110: 3561–3563.
115. Gertz MA, Lacy MQ, Dispenzieri A et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007; 92: 1415–1418.
116. Vesole DH, Perez WS, Akasheh M et al. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc 2006; 81: 880–888.
117. Dispenzieri A, Gertz MA, Kyle RA et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881–1887.
118. Dispenzieri A, Kyle RA, Gertz MA et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787–1789.
119. Gertz MA, Lacy M, Dispenzieri A et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49: 36–041.
120. Skinner M, Sanchorawala V, Seldin DC et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140: 85–93.
121. Yagi S, Akaike M, Ozaki S. Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis. Intern Med. 2007; 46: 1705–1710.
122. Perfetti V, Siena S, Palladini G et al. Long--term results of risk adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary AL amyloidosis. Hematologica 2006; 91: 1635–1643.
123. Dispenzieri A, Kyle RA, Lacy MQ et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral stem cell transplantation. A case control study. Blood 2004; 103: 2949–2951.
124. Gertz MA, Lacy MQ, Dispenzieri A et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004; 34: 1025–1031.
125. Dispenzieri A, Kyle RA, Lacy MQ et al. Superior survival in primary systemic amyloidosis patients udergoing peripheral stem cell transplantation: a case control study Blood 2004; 103: 3960–3963.
126. Jaccard A, Moreau P, Leblond V et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 83–93.
127. Leung N, Gunderson H, Tan TS et al. Melphalan and dexamethason is less effective for patients with immunoglobulin light chain amyloidosis with high bone marrow plasmocytosis. Blood 2008; 112: 612, abstr. 1735.
128. Sanchorawala V, Seldin DC, Magnani B et al. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36: 597–600.
129. Madan S, Kumar S, Dispenzieri A et al. Outcomes with high dose therapy and peripheral blood stem cell transplantation for light chain amyloidosis with cardiac involvement. Blood 2009; 114: (Suppl. N 22): 223, abstr. 534.
130. Landau H, Hassoun H, Cohen AD et al. Adjuvant bortezomib and dexamethasone following risk adapted melphalan and stem cell transplant in systemic light chain amyloidosis. Blood 2009; 114: (Suppl. N 22): 222, abstr. 533.
131. Landau HJ, Hoffman J, Hassoun H et al. Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL). J Clin Oncol 2009; 27: 15, abstr. 8540.
132. Hoffman JE, Hassoun H, Landau H et al. Early adjuvant treatment after risk adapted autologou stem cell transplant for systemic light chain amyloidosis. Increased hospitalization and impaired immune recovery but improved responses and overall survival. Blood 2008; 112: 1143, abstr. 3329.
133. Cibeira MT, Sanchorawala V, Seldin DC et al. Outcome of AL amyloidosis after high--dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118: 4346–4352.
134. Goodman HJ, Gillmore JD, Lachmann HJ et al. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006; 134: 417–425.
135. Madan S, Kumar SK, Dispenzieri A et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012; 119: 1117–1122.
136. Schonland SO, Bochtler T, Perz J et al: Results of two consecutive phase II trials of patients with systemic AL amyloidosis treated with high--dose melphalan after induction and mobilization chemotherapy. 12th international symposium on amyloidosis abstracts. Amyloid 2010; 17: 80–81.
137. Gerz MA, Lacy MA, Bjornsson J et al. Fatal pulmonary toxicity releated to the administration of granulocyte colony stimulation factor in amyloidosis. A report and review of growth factor pulmonary toxicity. J. Hematotherapy and stem cell research 2000; 9: 635–643.
138. Haynes-Lattin BM, Kurtin PT, Fleming WH. Toxic megacolon, a life threteating complication of high dose therapy and autologous transplantation among patients with AL-amyloidosis. Bone Marrow Transplantation 2002; 30: 279–285.
139. Kumar S, Dispenzieri A, Lacy MQ et al. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001; 28: 381–385.
140. Kyle RA, Gertz MA, Lacy MQ et al. Localized AL amyloidosis of the colon: an unrecognized entity. Amyloid. 2003; 10: 36–41.
141. Gerz, MA, Lacy MQ, Dispenzieri A et al. Amyloidosis. Best Practice Research Clinical Hematology 2005; 18: 709–727.
142. Leung N, Slezak JM Bertstralh EJ. Acute renal insufficiency after high dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Amer J Kidney Dis 2005; 45: 102–111.
143. Fadia A, Casserly LF, Sanchorawala V et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL-amyloidosis. Kidney International 2003; 63: 1868–1878.
144. Vesole D, Waleska S, Peréz S et al. High dose therapy and autologout hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. A center for International blood and marrow transplant research center. Mayo Clin Proc 2006; 81: 880–888.
145. Spier BJ, Einstein M, Johnson EA et al. Amyloidosis presenting as lower gastrointestinal hemorrhage. WMJ 2008; 107: 40–43.
146. Röcken C, Erns J, Hund E et al. Interdisciplinary guidelines on the diagnosis and therapy for systemic amyloidosis – issued by German society of amyloid disease (www.amyloid.de) Deutsche Med Wochenschrift 2006; 131: 1–28.
147. United Kingdom Myeloma Forum: Guidelines on the diagnosis and management of AL-amyloidosis. Brit J. Hematology 2004; 125: 681–700.
148. Perfetti V, Siena S, Palladii G et al. Long term results of a risk adapted aproach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary AL amyloidosis. Hematologica 2006; 91: 1635–1643.
149. Mhaskar R, Kumar A, Behera M et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant 2009; 15: 893–902.
150. Sanchorawala V. Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Am J Blood Res 2012; 2: 9–17.
151. Schönland SO, Dreger P, de Witte T et al. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light--chain amyloidosis. Bone Marrow Transplant 2012; 47: 895–905.
152. Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 2011; 23: 214–220.
153. Mehta J, Dispenzieri A, Gertz MA. High--dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis. Biol Blood Marrow Transplant 2010; 16: 138–140; author reply 140–141.
154. Sanchorawala V, Wright DG, Seldin DC et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004; 33: 381–388.
155. Audard V, Matignon M, Weiss L et al. Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis. Am J Transplant 2009; 9: 236–240.
156. Mignot A, Varnous S, Redonnet M et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis 2008; 101:523–532.
157. Lacy MQ, Dispenzieri A, Hayman SR et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant 2008; 27: 823–829.
158. Mignot A, Bridoux F, Thierry A et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. Haematologica 2008; 93: e32–e35.
159. Sack FU, Kristen A, Goldschmidt H et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008; 33: 257–262.
160. Perz JB, Kristen AV, Rahemtulla A et al. Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clin Res Cardiol 2006; 95: 671–674.
161. Gillmore JD, Goodman HJ, Lachmann HJ et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006; 107: 1227–1229.
162. Dubrey SW, Burke MM, Hawkins PN et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004; 23: 1142–1153.
163. Kastritis E, Dimopoulos MA. Prognosis and risk assessment in AL amyloidosis – state of the art. Amyloid 2011; 18: (Suppl. 1): 84–86.
164. Mekinian A, Lions C, Leleu X et al. Amyloidosis Study Group. Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging. Am J Med 2010; 123: 864–868.
165. Kristen AV, Giannitsis E, Lehrke S et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010; 116: 2455–2461.
166. Kumar S, Dispenzieri A, Lacy MQ et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989–995.
167. Dispenzieri A, Gertz M, Kyle A et al. Serum cardiac troponins and N-terminal Pro-Brain Natriuretic Peptide: A staging system for primary AL-amyloidosis. J Clin Oncol 2004; 22: 3751–3757.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2013 Číslo 1
Najčítanejšie v tomto čísle
- Drug induced osteoporosis
- Specificities of the diagnostics and therapy of exocrine pancreatic insufficiency
- Risk factors for relapsing and severe Clostridium difficile infection
- Outcomes of Catheter Ablation of Atrial Fibrillation in Patients over 65 Years of Age